2025 fourth_quarter Filing
Q4Lobbying Activities
Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.